Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
85.95
-0.33 (-0.38%)
At close: Oct 29, 2026, 4:00 PM EDT
85.90
-0.05 (-0.06%)
After-hours: Oct 29, 2026, 4:35 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $256.15M in the quarter ending June 30, 2026, with 31.74% growth. This brings the company's total for the last twelve months to $830.81M, up 16.02% year-over-year. In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth. That makes Corcept Therapeutics the 8,498th largest company in the world by revenue and 1,912th in the United States.
Revenue (ttm)
$830.81M
Revenue Growth
+16.02%
P/S Ratio
11.21
Revenue / Employee
$1,138,100
Employees
730
Market Cap
9.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Madrigal Pharmaceuticals | 1.28B |
| Caris Life Sciences | 989.61M |
| Krystal Biotech | 440.48M |
| Twist Bioscience | 431.80M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
CORT News
- 2 days ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 3 days ago - Corcept announces results from Part A of Phase 2 BELLA trial of Lifyorli - TheFly
- 3 days ago - Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 9 days ago - 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes - Business Wire
- 14 days ago - Why Healthcare Stocks Are Hot When the AI Trade Runs Cold - Barrons
- 5 weeks ago - Corcept Therapeutics president of endocrinology Sean Maduck to retire - TheFly
- 5 weeks ago - Corcept Announces Planned Leadership Transition - Business Wire
- 5 weeks ago - Corcept announces positive CHMP opinion for Lifyorli - TheFly